Item does not contain fulltextThe EORTC Melanoma Group (MG) was founded in 1969 by both clinicians and scientists from various disciplines and fields of research with a common interest in malignant melanoma. This collaborative approach has always been the foundation of the groups strength. With an interest in tumour biology and especially the immunological aspects of the disease, the group has always pursued a scientific approach to treatment development in malignant melanoma. Over the years, the group has performed many clinical trials, epidemiological studies, histopathological studies defining standards and guidelines, translational research regarding prognostic factors and various metastatic and immunological aspects of melanoma, and de...
Contains fulltext : 19619.pdf (publisher's version ) (Open Access)Melanoma is one ...
Background: The objectives and goals of the Southern Swedish Malignant Melanoma (SSMM) are to develo...
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin...
The EORTC Melanoma Group (MG) was founded in 1969 by both clinicians and scientists from various dis...
Last year the Melanoma Group of the European Organization for Research and Treatment of Cancer (EORT...
In the framework of the European Organisation for Research and Treatment of Cancer (EORTC), the Immu...
Since its inception in 1969, the EORTC Melanoma Group has employed a multidisciplinary approach in t...
AbstractSince its inception in 1969, the EORTC Melanoma Group has employed a multidisciplinary appro...
Item does not contain fulltextThe EORTC Leukemia Group comprises more than 45 qualified haematology ...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...
The EORTC Breast Cancer Group (EBCG) is a multidisciplinary international group created in 1962 in c...
AbstractAfter more than 30 years of clinical and translational research, and having contributed to l...
AbstractThe EORTC Breast Cancer Group (BCG), created in 1962, is a multidisciplinary group involving...
Malignant melanomas, although less common than most malignancies, account for 1% of all cancers, and...
Improvement in cancer care is possible by applying new treatment modalities, which are emerging from...
Contains fulltext : 19619.pdf (publisher's version ) (Open Access)Melanoma is one ...
Background: The objectives and goals of the Southern Swedish Malignant Melanoma (SSMM) are to develo...
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin...
The EORTC Melanoma Group (MG) was founded in 1969 by both clinicians and scientists from various dis...
Last year the Melanoma Group of the European Organization for Research and Treatment of Cancer (EORT...
In the framework of the European Organisation for Research and Treatment of Cancer (EORTC), the Immu...
Since its inception in 1969, the EORTC Melanoma Group has employed a multidisciplinary approach in t...
AbstractSince its inception in 1969, the EORTC Melanoma Group has employed a multidisciplinary appro...
Item does not contain fulltextThe EORTC Leukemia Group comprises more than 45 qualified haematology ...
textabstractAfter more than 30 years of clinical and translational research, and having contributed ...
The EORTC Breast Cancer Group (EBCG) is a multidisciplinary international group created in 1962 in c...
AbstractAfter more than 30 years of clinical and translational research, and having contributed to l...
AbstractThe EORTC Breast Cancer Group (BCG), created in 1962, is a multidisciplinary group involving...
Malignant melanomas, although less common than most malignancies, account for 1% of all cancers, and...
Improvement in cancer care is possible by applying new treatment modalities, which are emerging from...
Contains fulltext : 19619.pdf (publisher's version ) (Open Access)Melanoma is one ...
Background: The objectives and goals of the Southern Swedish Malignant Melanoma (SSMM) are to develo...
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin...